US FDA’s Post-Aduhelm Reforms Include Updated Alzheimer’s Development Guidance, Record-Keeping On Sponsor Meetings
• By M. Nielsen Hobbs
FDA will continue to have to navigate the treacherous seas of the Aduhelm controversy in 2023. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
